Cytonus Therapeutics Inc.
Columbus, OH Doing business as Cytonus Therapeutics Inc.
- UEI
- UBM9DERRCXZ9
- CAGE
- 8DAU4
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 111 E Deshler Ave, Columbus, OH 43206, USA
- Website
- cytonus.com
- Founded
- 2018
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of CA-IL-12 for triple negative breast cancer - most cancer patients DIE as a result of metastatic disease… | National Cancer Institute | $3,190,757 | |
| Targeted therapeutic delivery to diseased lungs using enucleated mesenchymal stem cells - there is critical need for… | National Heart Lung and Blood Institute | $892,659 | |
| Bioengineering a novel therapeutic transporter that crosses the blood brain barrier to treat brain disorders - while the… | National Center for Advancing Translational Sciences | $974,958 | |
| Therapeutic platform to treat disease lung using enucleated mesenchymal stem CELLS0/01/2021 - there is critical need for… | National Heart Lung and Blood Institute | $1,819,900 | |
| Development of a novel therapeutic transporter to treat metastatic cancers | National Cancer Institute | $399,346 |
About Cytonus Therapeutics Inc.
Cytonus Therapeutics Inc. is a for-profit biotechnology company focused on developing cell-based therapeutic delivery platforms, called CargoCystesTM, to precisely deliver drugs and biologics to diseased tissues. Through past federal grants, Cytonus has conducted research to engineer CargoCystes that can home to and deliver therapeutics within metastatic tumors, the brain across the blood-brain barrier, and inflamed lung tissues.
Cytonus Therapeutics has received over $6 million in federal grant funding to support the development of its CargoCystes technology. This includes Project Grants from the National Cancer Institute, National Heart Lung and Blood Institute, and National Center for Advancing Translational Sciences within the Department of Health and Human Services. The grants have funded proof-of-concept research on using genetically engineered and enucleated mesenchymal stem cells to transport and deliver interleukin-12, antibodies, RNAs and other therapeutic agents specifically to primary and metastatic tumors, ischemic areas of the brain, and damaged lung tissues. If successful, CargoCystes could provide targeted delivery of potent biologics while avoiding systemic toxicity.
Quick answers
What is Cytonus Therapeutics Inc.'s UEI?
Cytonus Therapeutics Inc.'s Unique Entity ID (UEI) in SAM.gov is UBM9DERRCXZ9.
What is Cytonus Therapeutics Inc.'s CAGE code?
Cytonus Therapeutics Inc.'s CAGE code is 8DAU4.
What is Cytonus Therapeutics Inc.'s primary NAICS code?
Cytonus Therapeutics Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Cytonus Therapeutics Inc. located?
Cytonus Therapeutics Inc.'s physical address in SAM.gov is 111 E Deshler Ave, Columbus, OH 43206, USA.
Is Cytonus Therapeutics Inc. registered in SAM.gov?
Yes. Cytonus Therapeutics Inc.'s SAM.gov registration is active through June 29, 2027.
What is Cytonus Therapeutics Inc.'s most recent federal award?
Cytonus Therapeutics Inc.'s most recent federal grant award is Development of CA-IL-12 for triple negative breast cancer - most cancer patients DIE as a result of metastatic disease… (R44CA250887), from National Cancer Institute, on September 1, 2023.
On GovTribe
See Cytonus Therapeutics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors